| Year |
Citation |
Score |
| 2024 |
Roy Chaudhuri T, Lin Q, Stachowiak EK, Rosario SR, Spernyak JA, Ma WW, Stachowiak MK, Greene MK, Quinn GP, McDade SS, Clynes M, Scott CJ, Straubinger RM. Dual-hit strategy for therapeutic targeting of pancreatic cancer in patient-derived xenograft tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38270582 DOI: 10.1158/1078-0432.CCR-23-0131 |
0.486 |
|
| 2020 |
Greene MK, Chen T, Robinson E, Straubinger NL, Minx C, Chan DKW, Wang J, Burrows JF, Van Schaeybroeck S, Baker JR, Caddick S, Longley DB, Mager DE, Straubinger RM, Chudasama V, ... Scott CJ, et al. Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. British Journal of Cancer. PMID 32913288 DOI: 10.1038/S41416-020-01046-6 |
0.494 |
|
| 2020 |
Johnston MC, Nicoll JA, Redmond KM, Smyth P, Greene MK, Wj M, Dkw C, Crawford N, Stott KJ, Fox JP, Straubinger NL, Roche S, Clynes M, Straubinger RM, Longley DB, ... Scott CJ, et al. DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 32504778 DOI: 10.1016/J.Jconrel.2020.05.046 |
0.504 |
|
| 2019 |
McDaid WJ, Greene MK, Johnston MC, Pollheimer E, Smyth P, McLaughlin K, Van Schaeybroeck S, Straubinger RM, Longley DB, Scott CJ. Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours. Nanoscale. PMID 31626255 DOI: 10.1039/C9Nr07257H |
0.504 |
|
| Show low-probability matches. |